BENITEC BIOPHARMA LTD ADR
NASDAQ: BNTC (Benitec Biopharma Inc.)
Last update: 2 days ago, 9:01PM14.99
-0.06 (-0.40%)
| Previous Close | 15.05 |
| Open | 14.44 |
| Volume | 5,400 |
| Avg. Volume (3M) | 45,391 |
| Market Cap | 382,939,040 |
| Price / Sales | 2.77 |
| Price / Book | 4.63 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 - 16 May 2025 |
| Diluted EPS (TTM) | -0.620 |
| Total Debt/Equity (MRQ) | 0.18% |
| Current Ratio (MRQ) | 25.48 |
| Operating Cash Flow (TTM) | -21.75 M |
| Levered Free Cash Flow (TTM) | -15.39 M |
| Return on Assets (TTM) | -29.99% |
| Return on Equity (TTM) | -46.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Benitec Biopharma Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 0.0 |
| Average | -0.50 |
|
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.20% |
| % Held by Institutions | 82.21% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Infinitum Asset Management, Llc | 31 Dec 2024 | 210,000 |
| Simplify Asset Management Inc. | 31 Dec 2024 | 76,337 |
| Lion Point Capital, Lp | 31 Dec 2024 | 62,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 28.00 (HC Wainwright & Co., 86.79%) | Buy |
| Median | 20.00 (33.42%) | |
| Low | 18.00 (Citizens Capital Markets, 20.08%) | Buy |
| Average | 22.00 (46.77%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 13.93 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 10 Apr 2025 | 20.00 (33.42%) | Buy | 11.94 |
| HC Wainwright & Co. | 24 Mar 2025 | 28.00 (86.79%) | Buy | 14.34 |
| 21 Feb 2025 | 28.00 (86.79%) | Buy | 11.30 | |
| Citizens Capital Markets | 18 Mar 2025 | 18.00 (20.08%) | Buy | 15.52 |
No data within this time range.
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 01 Jun 2018 | - | 08 Jun 2018 | 0.002929 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2018 | 0.003 | 1 | 0.00 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |